No description available.

No description available.

Polymorphisms of platelet glycoproteins (GPs) are frequently targets for anti-platelet antibodies. At least 19 antigenic polymorphisms have been identified on platelet GPs. Antibodies against the HPA-lb polymorphism (a Leu to Pro switch at amino acid residue 33 of the IIIa sub-unit of GP IIb/Illa) have been attributed to as much as 90% of all cases of neonatal alloimmune thrombocytopenic purpura and posttransfusion purpura in caucasians. The HPA-lb polymorphism has also been equivocally associated with coronary artery disease, particularly early onset (<60 years of age) myocardial infarction. Current technology for identifying individuals with the HPA-lb phenotype is limited to the labor-intensive, highly technical and expensive process of DNA amplification by polymerase chain reaction and restriction fragment length polymorphism (PCR/RFLP) analysis.This study proposes an alternative method for phenotyping individuals for the HPA-1 polymorphism using the Biocytex Platelet HPA-1 kit. The kit identifies the HPA-1 polymorphism utilizing two monoclonal CD61 (platelet glycoprotein IIb/IIIa) antibodies, one of which has a lowered affinity for GP llb/Illa possessing the HPA-lb polymorphism. Fluorescent labeling of bound antibody allows for flow cytometric quantitation of antibody binding capacity (ABC) for both monoclonal antibodies, and ratios derived from the ABC can be used to phenotype previously unknown samples.The Biocytex HPA-1 kit identified 73 of 74 (98.6%) individuals possessing the HPA1 a/HPA-1 a phenotype, 22 of 22 (100%) HPA-1 a/HPA-1 b individuals and 4 of 4 (100%) HPAIb/HPA-Ib individuals. All HPA-lb phenotypes were confirmed by PCR/RFLP. Total accuracy of the test system was 99%. / Department of Biology

Thesis--Helsinki. / Includes bibliographical references.

Thesis (M. Phil.)--University of Hong Kong, 2005. / Title proper from title frame. Also available in printed format.

Thesis (M.S.)--University of Michigan, 1995. / Thesis date on spine.

Thesis (M.S.)--University of Michigan, 1995. / Thesis date on spine.

Inherited disorders of platelet function are a rare and heterogeneous group of diseases usually characterised by a mild to moderate bleeding tendency. Typical bleeding symptoms are easy bruising, epistaxis, menorrhagia as well as mucocutaneous and perioperative bleeding. The performance of platelet function diagnostics in children is hampered by age-dependent restriction of blood sample size, poor venous access, and the lack of reproducible test reference ranges for children of different age groups. Platelet function testing is limited to specialised centres, because platelet function test procedures are complicated and time-consuming, which most likely results in a relevant number of undiagnosed and incorrectly classified children with clinically relevant platelet function defects. Evaluation of bleeding history and bleeding symptoms is essential for a rational step-bystep approach to diagnosis. Platelet function diagnostics should be preceded by the exclusion of thrombocytopenia, von Willebrand disease, and secondary haemostasis defects. Light transmission aggregometry is still considered the standard for the assessment of platelet function. Every effort should be made to classify the specific platelet function defect in the patient, because this is essential for accurate treatment and counselling. / Angeborene Thrombozytenfunktionsstörungen stellen eine seltene und heterogene Gruppe von Erkrankungen dar, welche meist durch eine leichte bis mittelschwere Blutungsneigung auffallen. Typische Blutungssymptome sind Hämatomneigung, Epistaxis, Menorrhagien sowie Schleimhaut- und perioperative Blutungen. Die Durchführung der Thrombozytenfunktionsdiagnostik bei Kindern wird erschwert durch die altersabhängig begrenzte Blutprobenmenge, schwierige Venenverhältnisse und das Fehlen von Referenzbereichen für Kinder unterschiedlichen Alters. Aufgrund der meist komplizierten und zeitaufwendigen Tests ist die Thrombozytendiagnostik auf spezialisierte Zentren begrenzt. Mit hoher Wahrscheinlichkeit wird eine relevante Anzahl von Kindern mit nichtdiagnostizierten bzw. unkorrekt klassifizierten, klinisch relevanten Thrombozytopathien übersehen. Die Erhebung der Blutungsanamnese und die Bewertung der Blutungssymptome sind erforderlich für eine stufenweise erfolgreiche Gerinnungsdiagnostik. Vor Durchführung einer Thrombozytenfunktionsdiagnostik sollten das Vorliegen einer Thrombozytopenie, einer von-Willebrand-Erkrankung und sekundärer Gerinnungsstörungen ausgeschlossen werden. Die Lichttransmissionsaggregometrie gilt noch immer als Standardmethode für die Beurteilung der Thrombozytenfunktion. Nach Möglichkeit sollte stets versucht werden, den vorliegenden spezifischen Thrombozytenfunktionsdefekt zu klassifizieren, da dies für eine adäquate Behandlung und eine gezielte genetische Beratung notwendig ist. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Si le phénomène bullaire reste le primum movens à l’origine de l’obstruction vasculaire lors de la décompression, les plaquettes sanguines jouent un rôle déterminant dans la physiopathologie de l’accident de décompression (ADD). L’objectif de ces travaux était d’étudier les mécanismes à l’origine de cette agrégation plaquettaire induit par le phénomène bullaire. La première étape a permis de valider un modèle animal d’ADD chez le rat et de confirmer que le degré d’agrégation constituait un indice fiable de sévérité de l’ADD. La seconde a eu pour but d’étudier différents marqueurs spécifiques de l’activation plaquettaire. La troisième étape a étudié les effets de différents anti-agrégants plaquettaires administrés avant l’exposition. Les résultats confirment que le clopidogrel, un inhibiteur spécifique des récepteurs à l’ADP, a un effet protecteur sur le risque de survenue et la sévérité des ADD en réduisant l’importance de l’agrégation plaquettaire. Ces résultats sont en faveur d’un mécanisme d’agrégation ADP-dépendant conséquence des interactions entre les plaquettes et les bulles circulantes. La génération de thrombine, un autre puissant agoniste plaquettaire, interviendrait dans la genèse d’un état pro-thrombotique loco-régional conséquence des lésions induites par le passage des bulles au contact de l’endothélium vasculaire. Enfin, les résultats montrent le rôle joué par les micro-particules dans la diffusion à distance de cet état pro-thrombotique. Des études à venir devront confirmer l’intérêt d’une utilisation du clopidogrel dans le traitement de l’ADD ainsi que le rôle de l’oxyde nitric, de la prostacycline PGI2 et du shear-stress dans l’effet protecteur des vibrations et de l’exercice physique sur le risque de survenue de l’ADD en réduisant l’agrégation plaquettaire et en optimisant la cinétique d’élimination des bulles circulantes. / If bubble-induced mechanical obstruction of vessels is the central event during decompression, blood platelets play a key role in the pathogenesis of decompression sickness (DCS). But bubble-induced platelet aggregation (BIPA) mechanisms are unknown. In a previous study, we highlighted a post-dive decrease in platelet count in divers. The aims of this study was therefore to validate an experimental model of DCD in rat to clarify relationship between blood platelet and bubble formation, investigate platelet activation by measuring different platelet markers, and to study the effects of different antithrombotic pre-treatments. First, the results clearly indicate that clopidogrel, a powerful ADP-inhibitor, has a protective effect on decompression risk improving significantly DCS outcome and reducing DCS severity. The results point to the predominant involvement of the ADP release in the BIPA mechanism. Second, we showed the participation of thrombin generation, a powerful platelet agonist, in the thrombotic event. If local BIPA seems to be the direct consequence of bubble-blood component interactions in vascular bed, the regional thrombotic event could be the consequence of bubble-induced vessel wall injury with a key role played by micro-particles in the general extend. Further human studies should be aimed at demonstrating that clopidogrel can offer a benefit as an adjuvant in DCS treatment and the role played by nitric oxyd and prostacyclin in the protective effect of vibrations and physical exercise on DCS risk reducing bubble-induced platelet aggregation

Introdução: A doação de plaquetas por aférese é um método de coleta que vem aumentando em relevância. Sabe-se que esta técnica apresenta inúmeras vantagens em comparação à doação de sangue total. Observamos que há uma preocupação na qualidade dos hemocomponentes enviados ao paciente, no entanto, não se observam muitas pesquisas em busca do cuidado com o doador. Órgãos como o Food and Drug Administration (FDA) já publicaram normas mais restritivas em relação à doação de plaquetas por aférese, pois pesquisas apontaram uma diminuição de algumas células e proteínas do sistema imunológico em doadores de repetição. Objetivos: Analisar doadores de plaquetas de repetição quanto a parâmetros hematimétricos e quantificação de subpopulações linfocitárias comparando-os com um grupo controle composto por doadores de sangue total que não doam há no mínimo um ano ou doando pela primeira vez e, ainda avaliar se a frequência de doações, o tempo de procedimento e o número de plaquetas doadas influenciam na contagem de leucócitos totais e nas subpopulações de linfócitos. Metodologia: Foram analisados 88 indivíduos em um estudo caso-controle, sendo que o grupo controle (CO) incluído foi de doadores de sangue total que haviam doado pela primeira vez ou haviam doado sangue total há mais de um ano. Os casos (CA) incluídos foram os doadores de repetição de plaquetaférese (quatro ou mais doações no último ano). O pareamento foi feito por sexo e idade. As amostras de sangue periférico foram coletadas em tubos contendo EDTA e analisadas em até 6 horas por citometria de fluxo, através da utilização de anticorpos monoclonais anti-CD3, CD4, CD8, HLADR, CD19 e CD56. Resultados: Foram avaliados 44 pares de doadores (caso vs controle). Destes, 81,8% eram homens, a média de idade dos grupos foi de 46 ±13 anos nos casos e 47 ±11 nos controles. Comparando os dois grupos, observou-se diferença estatisticamente significativa (p<0,05) na média de quantificação de leucócitos absolutos CA= 6476,6/μL vs CO=7115,4/μL (p=0,017), na média de linfócitos absolutos CA= 1862,6/μL vs CO= 2239,2/μL (p=0,007) e nos marcadores: CD3+/CD8+ (absoluto) CA= 437/μL vs CO= 597/μL (p=0,01), CD3+/CD4+(%) CA= 47,3/μL vs CO= 42,77/μL (p=0,007). Conclusões: Neste estudo foi possível observar que há uma diminuição em algumas células linfoides dos doadores de repetição em relação aos doadores convencionais, no entanto essa diferença não tem relevância clínica, demonstrando que os intervalos de doações que estes doadores estão sendo submetidos é adequado. A contagem de plaquetas dos doadores de repetição se mantiveram no decorrer do ano, este dado nos auxilia para mantermos um banco de dados de doadores de repetição com uma quantificação de plaquetas adequada, podendo ser convocado sem risco de ser bloqueado por contagem inferior ao preconizado. / Introduction: The donation of platelets by apheresis as a collection method has lately grown in relevance. This technique presents several advantages when compared to total blood donation. We understand there is a concern about the quality of the hemocomponents that are administered to the patients; however, there are not many researches concerned with caring for the donor. Entities such as the Food and Drug Administration (FDA) have published more restricting regulations regarding the donation of platelets by apheresis, since researches indicate a decrease in some cells and proteins present in the immunological systems of repeat donors. Objectives: To analyze repeat donors of platelets with regards to hematimetric parameters and quantification of lymphocyte sub-populations by comparing them with a control group consisting of total blood donors that have not donated blood for the past year at least or that are donating for the first time. Additionally, to evaluate if the frequency of donations, the duration of the procedure, and the donated platelet counts influence in the total leukocyte counts and in the sub-populations of lymphocytes. Methodology: We analyzed 88 individuals in a control case study. The control group (CG) consisted of total blood donors in their first donation or that had donated for the last time more than a year before. The cases (CA) included were the repeat donors by platelet apheresis (four or more donations in the past year). We matched the individuals by gender and age. Peripheral blood samples were collected in tubes containing EDTA and analyzed up until 6 hours later by flow cytometry, through monoclonal antibodies anti-CD3, CD4, CD8, HLADR, CD19, and CD56. Results: 44 pairs of donor were evaluated (case vs control). Among them, 81.8% were men, the average age of the groups was 46 (±13) years in the cases and 47 (±11) in the controls. When comparing the two groups, we observed a statistically significant difference (p<0,05) in the average of the quantification of absolute leukocytes CA= 6476.6/μL vs CG=7115.4/μL (p=0.017), in the average of absolute lymphocytes CA= 1862.6/μL vs CG= 2239.2/μL (p=0.007), and in the markers: CD3+/CD8+ (absolute) CA= 437/μL vs CG= 597/μL (p=0,01), CD3+/CD4+(%) CA= 47.3/μL vs CG= 42.77/μL (p=0.007). Conclusions: We were able to note in this study that there is a significant decrease in some lymphoid cells of repeat donors when compared to conventional donors. This difference, however, is not clinically relevant, which demonstrates that the donation intervals to which the donors are subject are appropriate. Platelet numbers of repeat donors remained the same throughout the year. This piece of data helps us keep a database of repeat donors with an adequate platelet number. These donors can be called for without risking of their being blocked in the screening for a number lower than the recommended.